Compare ACR & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACR | VTVT |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.3M | 127.0M |
| IPO Year | N/A | 2015 |
| Metric | ACR | VTVT |
|---|---|---|
| Price | $23.76 | $35.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $24.50 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 50.5K | 12.6K |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.65 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $88,952,000.00 | $17,000.00 |
| Revenue This Year | $4.05 | N/A |
| Revenue Next Year | $0.38 | N/A |
| P/E Ratio | $24.86 | ★ N/A |
| Revenue Growth | ★ 14.87 | N/A |
| 52 Week Low | $14.94 | $13.15 |
| 52 Week High | $24.17 | $35.95 |
| Indicator | ACR | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 68.90 | 72.05 |
| Support Level | $22.74 | $32.84 |
| Resistance Level | $23.99 | $35.95 |
| Average True Range (ATR) | 0.90 | 2.17 |
| MACD | 0.19 | 0.67 |
| Stochastic Oscillator | 89.43 | 97.41 |
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.